Black Diamond Therapeutics (BDTX) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Black Diamond Therapeutics (BDTX) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 65.5% versus a loss of 85.7%. Black Diamond Therapeutics is the larger company by market cap ($75.3 million vs $63.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | NMRA |
|---|---|---|
| Share price | $1.31 | $0.3339 |
| Market cap | $75.28M | $63.01M |
| 1-day change | -5.76% | -3.78% |
| YTD return | -46.09% | -81.35% |
| 1-year return | -65.53% | -85.67% |
| 5-year return | -79.30% | — |
| EPS (TTM) | $-0.77 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $70.00M | — |
| Net income (latest FY) | $22.37M | $-236.93M |
| Operating margin | 17.89% | — |
| Net margin | 31.95% | — |
| 52-week high | $3.97 | $3.65 |
| 52-week low | $1.31 | $0.301 |
| Distance from 52-week high | -67.00% | -90.85% |
| Analyst consensus | none | buy |
| Avg. price target upside | +663.36% | +1696.95% |
| Average volume | 697.70K | 1.69M |
| Shares outstanding | 57.47M | 188.69M |
| Employees | 21 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BDTX has outperformed NMRA by 20.1 percentage points over the past year.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
BDTX vs NMRA FAQ
Which is bigger, Black Diamond Therapeutics or Neumora Therapeutics?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $75.28M compared with $63.01M for Neumora Therapeutics (NMRA).
Which stock has performed better over the past year, BDTX or NMRA?
BDTX returned -65.53% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.